| Literature DB >> 33137864 |
Yae Ji Choi1, Woo Yeon Hwang1, Nara Lee2, Miseon Kim2, Dong Hoon Suh1, Kidong Kim1, Yong Beom Kim1, Jae Hong No1.
Abstract
OBJECTIVE: To investigate clinical features that affect the number of pelvic lymph nodes (PLNs) harvested and prognostic significance of the number of PLNs removed in patients with stage IB1 to IIA2 cervical cancer.Entities:
Keywords: Lymph node excision; Lymph nodes; Uterine cervical neoplasms
Year: 2020 PMID: 33137864 PMCID: PMC7834762 DOI: 10.5468/ogs.20016
Source DB: PubMed Journal: Obstet Gynecol Sci ISSN: 2287-8572
Clinicopathologic characteristics of the patients
| Variables | No. of patients (n=210) | Value |
|---|---|---|
| Age | ||
| Mean | 47 (25–81) | |
| <50 | 114 | 54.3 |
| ≥50 | 96 | 45.7 |
| Body weight (kg) | ||
| Mean | 57.6±8.17 | |
| <60 | 142 | 67.6 |
| ≥60 | 68 | 32.4 |
| Height (cm) | ||
| Mean | 157.3±6.68 | |
| <159.6 | 130 | 61.9 |
| ≥159.6 | 80 | 38.1 |
| Body mass index (kg/m2) | ||
| Mean | 23.34±3.54 | |
| <25 | 152 | 72.4 |
| ≥25 | 58 | 27.6 |
| FIGO clinical stage | ||
| IB1 | 148 | 70.5 |
| IB2 | 46 | 21.9 |
| IIA1 | 12 | 5.7 |
| IIA2 | 4 | 1.9 |
| Histology | ||
| Non-SCC | 90 | 42.9 |
| SCC | 120 | 57.1 |
| Tumor size (cm) | ||
| <4 | 150 | 71.4 |
| ≥4 | 60 | 28.6 |
| LVSI | ||
| No | 110 | 52.4 |
| Yes | 100 | 47.6 |
| Harvested PLN | ||
| Mean | 23.13±11.66 | |
| <23 | 110 | 52.4 |
| ≥23 | 100 | 47.6 |
| PLN metastasis | ||
| No | 168 | 80.0 |
| Yes | 42 | 20.0 |
| Adjuvant CCRT | ||
| No | 118 | 56.2 |
| Yes | 92 | 43.8 |
Value are shown as mean±standard deviation or number (%). FIGO, International Federation of Gynecology and Obstetrics; SCC, squamous cellular carcinoma; LVSI, lymphovascular space invasion; PLN, pelvic lymph node; CCRT, concurrent chemo-radiation therapy.
Clinicopathologic factors affecting the number of harvested pelvic lymph nodes (PLNs)
| Variables | Harvested PLN | OR | 95% CI | |||
|---|---|---|---|---|---|---|
| <23 | ≥23 | |||||
| Age | <50 | 58 | 56 | 0.876 | 0.509–1.510 | 0.634 |
| ≥50 | 52 | 44 | ||||
| BMI (kg/m2) | <25 | 82 | 70 | 1.255 | 0.685–2.300 | 0.462 |
| ≥25 | 28 | 30 | ||||
| Body weight (kg) | <60 | 82 | 60 | 1.952 | 1.086–3.510 | 0.024 |
| ≥60 | 28 | 40 | ||||
| Height (cm) | <159.6 | 75 | 55 | 1.753 | 1.000–3.076 | 0.049 |
| ≥159.6 | 35 | 45 | ||||
| CCRT | No | 70 | 48 | 1.896 | 1.092–3.293 | 0.023 |
| Yes | 40 | 52 | ||||
| LN metastasis on MRI | No | 66 | 48 | 1.594 | 0.921–2.758 | 0.095 |
| Yes | 44 | 51 | ||||
| LN metastasis on PET | No | 71 | 33 | 2.613 | 1.152–5.926 | 0.019 |
| Yes | 14 | 17 | ||||
| LN metastasis on CT | No | 63 | 46 | 1.574 | 0.912–2.715 | 0.102 |
| Yes | 47 | 54 | ||||
| Tumor size (cm) | <4 | 91 | 59 | 3.328 | 1.764–6.280 | <0.001 |
| ≥4 | 19 | 41 | ||||
| LVSI | No | 59 | 51 | 1.111 | 0.646–1.912 | 0.702 |
| Yes | 51 | 49 | ||||
| Operation method | Laparotomy | 40 | 74 | 0.201 | 0.111–0.363 | <0.001 |
| Laproscopy | 70 | 26 | ||||
| Pathologically confirmed metastasis | No | 96 | 72 | 2.667 | 1.310–5.427 | 0.006 |
| Yes | 14 | 28 | ||||
OR, odds ratio; CI, confidence interval; BMI, body mass index; CCRT, concurrent chemo-radiation therapy; LN, lymph node; MRI, magnetic resonance imaging; PET, positron emission tomography; CT, computed tomography; LVSI, lymphovascular space invasion.
Multivariate logistic regression analysis of independent factors affecting the number of harvested pelvic lymph nodes
| Variables | Beta | SE | OR | 95% CI | |
|---|---|---|---|---|---|
| Body weight (≥60 kg) | 0.485 | 0.437 | 1.624 | 0.690–3.823 | 0.267 |
| Height (≥159.6 cm) | 0.910 | 0.422 | 2.484 | 1.086–5.682 | 0.031 |
| LN metastasis on MRI | 0.496 | 0.423 | 1.642 | 0.716–3.765 | 0.241 |
| LN metastasis on PET | 0.180 | 0.531 | 1.198 | 0.423–3.395 | 0.734 |
| Tumor size (≥4 cm) | 1.516 | 0.555 | 4.555 | 1.536–13.506 | 0.006 |
| Surgery method | −0.360 | 0.487 | 0.698 | 0.268–1.813 | 0.460 |
SE, standard error; OR, odds ratio; CI, confidence interval, LN, lymph node; MRI, magnetic resonance imaging; PET, positron emission tomography.
Fig. 1Kaplan-Meier analysis of (A) disease free survival (DFS) and (B) overall survival (OS) post-surgery of both groups with a cut-off based on the average number of pelvic lymph nodes (PLNs) harvested.
Fig. 2Kaplan-Meier analysis of (A) disease free survival (DFS) and (B) overall survival (OS) post-surgery in the pelvic lymph node (PLN) positive patients of both groups with a cut-off based on the average number of PLNs harvested.